IP Library › Granted Patent US 9,925,142
Granted Patent B2
US 9,925,142 · App. 14/674,063 · Granted Mar 27, 2018

Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

Inventors: Pirouz M. Daftarian (Halifax, CA); Marc Mansour (Halifax, CA); Bill Pohajdak (Dartmouth, CA); Robert G. Brown (Dartmouth, CA); Wijbe M. Kast (Flintridge, CA)
Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
A61K9/127A61K9/0024A61K31/4745A61K39/00A61K39/0011A61K39/12A61K39/385A61K47/646C07K14/005C07K14/4748C12N9/90A01K2267/0331A61K2039/545A61K2039/55544A61K2039/55555A61K2039/55561A61K2039/55566A61K2039/585A61K2039/6031A61K2039/6037A61K2039/622A61K2039/627A61K2039/70C07K2319/00C12N2710/20022C12N2710/20034C12Y503/03012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,925,142
App. No.
14/674,063
Granted
Mar 27, 2018
Kind
B2
Abstract

The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.

Claims (11)

1. A method for inducing an enhanced cytotoxic T lymphocyte (CTL) response thereby treating cancer or inhibiting or preventing the growth or proliferation of cancer cells in a subject in need of cancer treatment comprising administering a composition comprising:

a carrier consisting essentially of oil or which is a water-in-oil emulsion, wherein the oil is mineral oil, nut oil or squalene;

liposomes;

at least one antigen comprising a CTL epitope; and

at least one T helper epitope:

wherein the antigen and the T helper epitope are encapsulated within said liposomes.

2. The method of claim 1 wherein the cancer is selected from the group consisting of: cervical, vulvar, melanoma, breast, lung, ovarian, multiple myelomna, B cell lymphoma, hepatoma, sarcoma, bladder, prostate cancer, thyroid, H/N tumors, colon, rectal, renal, pancreatic, gastric, adenocarcinoma, T cell leukemia, lymphosarcoma, uterine, esophageal, non-Hodgkin's lymphomas, endometrial, and RCC tumors.

3. The method of claim 1 , wherein said T helper epitope is a separate molecule from said antigen.

4. The method of claim 1 , wherein said antigen comprises said T helper epitope or wherein said antigen is fused to said T helper epitope.

5. The method of claim 1 , wherein said antigen comprises combination of CTL epitopes.

6. The method of claim 1 , wherein said CTL epitope is derived from a tumor-associated protein.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2024
From: IMMUNOVACCINE TECHNOLOGIES INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066209/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2023
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: HIMV LLC
Reel/Frame 065241/0073 →
CHANGE OF ADDRESS Recorded Feb 12, 2018
From: IMMUNOVACCINE TECHNOLOGIES INC.
To: IMMUNOVACCINE TECHNOLOGIES INC.
Reel/Frame 045312/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2015
From: DAFTARIAN, PIROUZ M.; MANSOUR, MARC; POHAJDAK, BILL; BROWN, ROBERT G.; KAST, WIJBE M.
To: IMMUNOVACCINE TECHNOLOGIES INC.
Reel/Frame 035327/0293 →
Priority Claims (3)
CA 2523032 · Oct 7, 2005 · national
CA 2533705 · Jan 13, 2006 · national
CA 2542212 · Apr 7, 2006 · national
Continuity (3)
Division 12083209
Provisional Application 60806573 · Jul 5, 2006
Related Publication 20150202152A1 · Jul 23, 2015